Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2021 07:00 ET | Source: Foghorn Therapeutics

Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update

-- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma --...
October 19, 2021 16:05 ET | Source: Foghorn Therapeutics

Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit

CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...